September 12, 2011

Ei Yamada, President and CEO
AnGes MG, Inc.
(Code No. 4563, TSE Mothers)
Contact: Fumihiko Suzuki, Director, Corporate Planning Dept.
Tel: +81-3-5730-2480

FOR IMMEDIATE RELEASE

**Completion of RAC Review by NIH**
**- Protocol for U.S. Phase III Clinical Trial on "Collategene™,"**
**Therapeutic Agent for Ischemic Disease -**

AnGes MG, Inc. is pleased to announce that its subsidiary, AnGes, Inc., (Maryland, U.S.) received a letter from the US NIH (National Institutes of Health), Recombinant DNA Advisory Committee (RAC) on September 2, 2011, notifying the completion of RAC) review on the protocol for a global phase III clinical trial in Europe and the U.S. on "Collategene™," therapeutic agent for limb ischemia.

The RAC review comprehensively evaluates research studies involving recombinant DNA research from scientific, medical, safety, ethical and social aspects. By going through this review, RAC ensures that the research studies are scientifically and medically sound, safe and ethical. The scientific community is made aware and the general public is reassured regarding the research being conducted.

On receiving the positive review from RAC, President and Chief Executive Officer, Ei Yamada commented as follows: "It has become apparent that our phase III clinical trial protocol has no scientific, safety or ethical issue of concern. We would like to start a global study promptly in order to deliver the research and development results on genetic treatment that AnGes has accumulated to patients with severe limb ischemia who have currently no treatment option."

This trend will have minimum effect on the business performance for the fiscal year of 2011. However, it is expected to contribute to the improvement in the medium and long term business performance.

###